Assessing the relationship between compliance with antidepressant therapy and employer costs among employees in the united states

Journal of Occupational and Environmental Medicine

Volumn 52, Issue 2, 2010, Pages 115-124

  Birnbaum, Howard G ^a   Ben Hamadi, Rym ^a   Kelley, David ^a   Hsieh, Matthew ^a   Seal, Brian ^b   Kantor, Evan ^a   Cremieux, Pierre Y ^a   Greenberg, Paul E ^a  

^a ANALYSIS GROUP   (United States)

^b Sanofiaventis   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDEPRESSANT AGENT;

ABSENTEEISM; ADULT; ARTICLE; BILLING AND CLAIMS; CONTROLLED STUDY; COST OF ILLNESS; DEPRESSION; DRUG COST; EMPLOYEE; EMPLOYER; FEMALE; HEALTH CARE; HEALTH SURVEY; HUMAN; MALE; PATIENT COMPLIANCE; WORKPLACE;

EID: 77049113262     PISSN: 10762752     EISSN: None     Source Type: Journal    
DOI: 10.1097/JOM.0b013e3181cb5b10     Document Type: Article

References (37)

1. Greenberg PE, Kessler RC, Birnbaum HG, et al. The economic burden of depression in the United States: how did it change between 1990 and 2000? J Clin Psychiatry. 2003;64:1465-1475.
2. Kessler RC, Berglund P, Demler O, et al. The epidemiology of major depressive disorder: results from the National Comorbidity Survey Replication (NCS-R). JAMA. 2003;289:3095-3105.
3. Rush AJ, Trivedi MH, Wisniewski SR, et al. Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report. Am J Psychiatry. 2006;163:1905-1917.
4. Kennedy JJ, Coyne JS, Sclar DA. Drug affordability and prescription noncompliance in the United States: 1997-2002. Clin Ther. 2004;26:607-614.
5. Keller MB, Hirschfeld RM, Demyttenaere K, Baldwin DS. Optimizing outcomes in depression: focus on antidepressant compliance. Int Clin Psychopharmacol. 2002;17:265-271.
6. Greenberg PE, Stiglin LE, Finkelstein SN, Berndt ER. The economic burden of depression in 1990. J Clin Psychiatry. 1993;54:405-418.
7. Kessler RC, Akiskal HS, Ames M, et al. Prevalence and effects of mood disorders on work performance in a nationally representative sample of U.S. workers. Am J Psychiatry. 2006;163:1561-1568.
8. Crown WH, Finkelstein S, Berndt ER, et al. The impact of treatment- resistant depression on health care utilization and costs. J Clin Psychiatry. 2002;63:963-971.
9. Corey-Lisle PK, Birnbaum H, Greenberg PE, Marynchenko MB, Claxton AJ. Identification of a claims data "signature" and economic consequences for treatment-resistant depression. J Clin Psychiatry. 2002;63:717-726.
10. Russell JM, Hawkins K, Ozminkowski RJ, et al. The cost consequences of treatment-resistant depression. J Clin Psychiatry. 2004;65:341-347.
11. Greenberg PE, Corey-Lisle PK, Birnbaum H, et al. Economic implications of treatment-resistant depression among employees. Pharmacoeconomics. 2004;22:363-373.
12. Antidepressant Medication Management. Washington, DC: The State of Health Care Quality, National Committee for Quality Assurance; 2006:19.
13. Berndt ER, Finkelstein SN, Greenberg PE, et al. Workplace performance effects from chronic depression and its treatment. J Health Econ. 1998;17: 511-535.
14. Kocsis JH, Frances AJ, Voss C, Mason BJ, Mann JJ, Sweeney J. Imipramine and social-vocational adjustment in chronic depression. Am J Psychiatry. 1988;145:997-999.
15. Mauskopf JA, Simeon GP, Miles MA, Westlund RE, Davidson JR. Functional status in depressed patients: the relationship to disease severity and disease resolution. J Clin Psychiatry. 1996;57:588-592.
16. Mintz J, Mintz LI, Arruda MJ, Hwang SS. Treatments of depression and the functional capacity to work. Arch Gen Psychiatry. 1992;49:761-768.
17. Simon GE, Katon W, Rutter C, et al. Impact of improved depression treatment in primary care on daily functioning and disability. Psychol Med. 1998;28:693-701.
18. Wang PS, Lane M, Olfson M, Pincus HA, Wells KB, Kessler RC. Twelvemonth use of mental health services in the United States: results from the National Comorbidity Survey Replication. Arch Gen Psychiatry. 2005;62: 629-640. (Pubitemid 40973438)
19. Akincigil A, Bowblis JR, Levin C, Walkup JT, Jan S, Crystal S. Adherence to antidepressant treatment among privately insured patients diagnosed with depression. Med Care. 2007;45:363-369.
20. Touchette DR, Shapiro NL. Medication compliance, adherence, and persistence: current status of behavioral and educational interventions to improve outcomes. J Manag Care Pharm. 2008;14(suppl S-d):s2-s10.
21. Sokol MC, McGuigan KA, Verbrugge RR, Epstein RS. Impact of medication adherence on hospitalization risk and healthcare cost. Med Care. 2005;43:521-1520
22. Robinson RL, Long Sr, Chang S, Able S, et al. Higher costs and therapeutic factors associated with adherence to NCQA HEDIS antidepressant medication management measures: analysis of administrative claims. J Manag Care Pharm. 2006;12:43-54.
23. Cantrell CR, Eaddy MT, Shah MB, Regan TS, Sokol MC. Methods for evaluating patient adherence to antidepressant therapy: a real-world comparison of adherence and economic outcomes. Med Care. 2006;44:300-303.
24. Katon W, Cantrell CR, Sokol MC, Chiao E, Gdovin JM. Impact of antidepressant drug adherence on comorbid medication use and resource utilization. Arch Intern Med. 2005;165:2497-2503.
25. Cramer JA, Roy A, Burrell A, et al. Medication compliance and persistence: terminology and definitions. Value Health. 2008;11:44-47.
26. Burton WN, Chen CY, Conti DJ, Schultz AB, Edington DW. The association of antidepressant medication adherence with employee disability absences. Am J Manag Care. 2007;13:105-112.
27. Kessler RC, Ames M, Hymel PA, et al. Using the WHO Health and Work Performance Questionnaire (HPQ) to evaluate the indirect workplace costs of illness. J Occup Environ Med. 2004;46(suppl 6):S23-S37.
28. Master Drug Data Base v2.5 (MDDB® ). Conshohocken, PA: Medi-Span® , Wolters Kluwer Health; 2008.
29. Sikka R, Xia F, Aubert RE. Estimating medication persistency using administrative claims data. Am J Managed Care. 2005;11:449-457.
30. Kessler RC, Barber C, Birnbaum HG, et al. Depression in the workplace: effects on short-term disability. Health Aff. 1999;18:163-171.
31. Kessler R, White LA, Birnbaum H, et al. Comparative and interactive effects of depression relative to other health problems on work performance in the workforce of a large employer. J Occup Environ Med. 2008;50:809-816.
32. Hoffman EJ, Mathew SJ. Anxiety disorders: a comprehensive review of pharmacotherapies. Mt Sinai J Med. 2008;75:248-262.
33. Sachs GS, Nierenberg AA, Calabrese JR, et al. Effectiveness of adjunctive antidepressant treatment for bipolar depression. N Engl J Med. 2007;356: 1711-1722.
34. Morley S, Eccleston C, Williams A. Systematic review and meta-analysis of randomized controlled trials of cognitive behaviour therapy and behaviour therapy for chronic pain in adults, excluding headache. Pain. 1999;80:1-13.
35. Demyttenaere K, Adelin A, Patrick M, Walthère D, Katrien de B, Michèle S. Six-month compliance with antidepressant medication in the treatment of major depressive disorder. Int Clin Psychopharmacol. 2008;23:36-42.
36. Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40:373-383.
37. Romano PS, Roos LL, Jollis J. Adapting a clinical comorbidity index for use with ICD-9-CM administrative data. J Clin Epidemiol. 1993;46:1075-1079.